A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers

Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial

(2020) Justin Taylor et al.   Lancet Haematology

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

(2019) Andrzej J. Jakubowiak et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

(2019) I.B. Vergote et al.   GYNECOLOGIC ONCOLOGY

FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models

(2018) Cristina Corno et al.   BIOCHEMICAL PHARMACOLOGY

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents

(2018) Trinayan Kashyap et al.   Oncotarget

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose

(2017) Marsha L. Crochiere et al.   Oncotarget

888PPRECLINICAL AND EARLY CLINICAL ACTIVITY OF THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) EXPORTIN 1 (XPO1) ANTAGONIST SELINEXOR (KPT-330) IN PATIENTS (PTS) WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER (OVCA)

(2017) J. Martignetti et al.   ANNALS OF ONCOLOGY

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

(2016) Ying Chen et al.   CLINICAL CANCER RESEARCH

XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II  to the Nucleus

(2016) P. Ranganathan et al.   CLINICAL CANCER RESEARCH

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

(2016) Albiruni R. Abdul Razak et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

(2016) Mrinal M. Gounder et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings

(2016) Christine M. Bestvina et al.   ONCOLOGIST

XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A

(2015) T. Miyake et al.   CLINICAL CANCER RESEARCH

XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer

(2015) I. Ferreiro-Neira et al.   CLINICAL CANCER RESEARCH

Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study

(2015) Naga Chalasani et al.   GASTROENTEROLOGY

Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer

(2015) S. Kazim et al.   MOLECULAR CANCER THERAPEUTICS

Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein

(2015) Jo Ishizawa et al.   PHARMACOLOGY & THERAPEUTICS

Promising SINEs for Embargoing Nuclear-Cytoplasmic Export as an Anticancer Strategy

(2014) D. S. P. Tan et al.   Cancer Discovery

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

(2013) Noriyuki Katsumata et al.   LANCET ONCOLOGY

Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

(2012) D. Miller et al.   GYNECOLOGIC ONCOLOGY

Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer

(2008) Aurelia Noske et al.   CANCER

CRM1-Mediated Nuclear Export of Proteins and Drug Resistance in Cancer

(2008) Joel Turner et al.   CURRENT MEDICINAL CHEMISTRY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation

(2008) Pauline J. van der Watt et al.   INTERNATIONAL JOURNAL OF CANCER